Advertisement
EVO vs GELS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a StrongBuy and GELS is a Hold.
EVO in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 12, 2026
EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 37 cases where EVO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EVO's RSI Oscillator exited the oversold zone, 29 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 185 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVO as a result. In 88 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EVO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (10.407). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Momentum Indicator for GELS turns negative, indicating new downward trend
GELS saw its Momentum Indicator move below the 0 level on September 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator turned negative. In 32 of the 34 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for GELS crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GELS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GELS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GELS's RSI Indicator exited the oversold zone, 18 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where GELS advanced for three days, in 49 of 61 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
GELS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.589) is normal, around the industry mean (10.407). P/E Ratio (-1.208) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. GELS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GELS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
EVO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 65 | |
P/E GROWTH RATING 1..100 | 1 | |
SEASONALITY SCORE 1..100 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| EVO | GELS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 87% | 4 days ago 90% |
| MACD ODDS (%) | 1 day ago 71% | N/A |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Advances ODDS (%) | 2 days ago 68% | 17 days ago 80% |
| Declines ODDS (%) | 7 days ago 80% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EVO’s FA Score shows that 1 FA rating(s) are green while GELS’s FA Score has 2 green FA rating(s).
- EVO’s FA Score: 1 green, 4 red.
- GELS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EVO’s TA Score shows that 5 TA indicator(s) are bullish while GELS’s TA Score has 4 bullish TA indicator(s).
- EVO’s TA Score: 5 bullish, 3 bearish.
- GELS’s TA Score: 4 bullish, 5 bearish.
Price Growth
EVO (@Pharmaceuticals: Generic) experienced а +8.45% price change this week, while GELS (@Pharmaceuticals: Generic) price change was -2.29% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.
Reported Earning Dates
EVO is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.00% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
EVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To EVO | 1D Price Change % | ||
|---|---|---|---|---|
| EVO | 100% | -1.28% | ||
| SNDL - EVO | 42% Loosely correlated | +0.78% | ||
| PRGO - EVO | 35% Loosely correlated | +2.89% | ||
| SUPN - EVO | 29% Poorly correlated | +2.09% | ||
| ACET - EVO | 26% Poorly correlated | -4.68% | ||
| ACB - EVO | 25% Poorly correlated | +0.25% | ||
More | ||||
GELS and
Correlation & Price change
A.I.dvisor tells us that GELS and SXTC have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GELS and SXTC's prices will move in lockstep.
| Ticker / NAME | Correlation To GELS | 1D Price Change % | ||
|---|---|---|---|---|
| GELS | 100% | -2.23% | ||
| SXTC - GELS | 25% Poorly correlated | -34.25% | ||
| HCM - GELS | 24% Poorly correlated | -0.63% | ||
| AMLX - GELS | 23% Poorly correlated | -1.58% | ||
| IRWD - GELS | 23% Poorly correlated | +0.56% | ||
| EVO - GELS | 22% Poorly correlated | -1.28% | ||
More | ||||